Molecular and cellular biology of prostate cancer

Cancer and Metastasis Reviews

Volumn 16, Issue 1-2, 1997, Pages 29-66

  Lalani, El Nasir ^a   Laniado, Marc Elie ^a   Abel, Paul David ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

cytogenetics; growth factors; ion channels; oncogenes; prostatic neoplasms

Indexed keywords

CYTOLOGY; HUMAN; MALE; MOLECULAR BIOLOGY; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW;

ADULT; AGED; AGED, 80 AND OVER; DISEASE PROGRESSION; GENES, RAS; GROWTH SUBSTANCES; HUMANS; ION CHANNELS; MALE; MIDDLE AGED; MUTATION; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOVASCULARIZATION, PATHOLOGIC; PROSTATE; PROSTATIC NEOPLASMS; RECEPTORS, GROWTH FACTOR; RECEPTORS, STEROID;

EID: 0030912781     PISSN: 01677659     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1005792206377     Document Type: Review

References (403)

1. Woolf SH: Screening for prostate cancer with prostate-specific antigen. An examination of the evidence. [Review]. N Engl J Med 333: 1401-1405, 1995
2. Parkin DM, Pisani P, Ferlay J: Estimates of the worldwide incidence of 18 major cancers in 1985. Int J Cancer 54: 594-606, 1993
3. Boyle P, Maisonneuve P, Napalkov P: Incidence of prostate cancer will double by the year 2030: the argument for. Eur Urol 29 (Suppl 2): 3-9, 1996
4. Jensen OM, Esteve J, Moller H, Renard H: Cancer in the European Community and its member states. Eur J Cancer 25: 1167-1256, 1990
5. Boring CC, Squires TS, Tong T: Cancer Statistics. CA. Cancer J Clin 44: 7-26, 1994
6. Boyle P, Maisonneuve P, Napalkov P: The threat to health and strategies for control. In: Peeling WB (ed) Questions and Uncertainties about Prostate Cancer, pp. 3-29, Oxford: Blackwell Science. 1996
7. Parker SL, Tong T, Bolden S, Wingo PA: Cancer Statistics 1996. CA. Cancer J Clin. 1996
8. Schroder FH, Boyle P: Screening for prostate cancer - necessity or nonsense? [Review]. Eur J Cancer 29A: 656-661, 1993
9. Potosky AL, Miller BA, Albertsen PC, Kramer BS: The role of increasing detection in the rising incidence of prostate cancer. JAMA 273: 548-552, 1995
10. Walsh PC: Using prostate-specific antigen to diagnose prostate cancer: sailing in uncharted waters [editorial; comment] [see comments]. Ann Intern Med 119: 948-949, 1993
11. Hall RR: Screening and early detection of prostate cancer will decrease morbidity and mortality from prostate cancer: the argument against. Eur Urol 29 (Suppl 2): 24-26, 1996
12. Kramer BS, Brown ML, Prorok PC, Potosky AL, Gohagan JK: Prostate cancer screening: what we know and what we need to know. Ann Intern Med 119: 914-923, 1996
13. Haenszel W, Kurihara M: Studies of Japanese migrants. I. Mortality from cancer and other diseases among Japanese in the United States. Natl Cancer Inst Monogr 40: 43-68, 1996
14. Anonymous: Primer on molecular control of prostate cancer growth. New Jersey: Whitehouse Station, Merck, 1994
15. Giovannucci E, Rimm EB, Colditz GA, Stampfer MJ, Ascherio A, Chute CC, Willett WCA: A prospective study of dietary fat and risk of prostate cancer [see comments]. J Natl Cancer Inst 85: 1571-1579, 1993
16. The alpha-tocopherol, beta-carotene cancer prevention study group. The effect of vitamin E and beta-carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med 330: 1029-1035, 1994
17. Corder EH, Guess HA, Hulka BS, Friedman GD, Sadler M, Vollmer RT, Lobaugh B, Drezner MK, Vogelman JH, Orentreich N: Vitamin D and prostate cancer: a prediagnostic study with stored sera [see comments]. Cancer Epidemiol Biomarkers Prev 2: 467-472. 1993
18. Morrison H, Savitz D, Semenciw R, Hulka B, Mao Y, Morison D, Wigle D: Farming and prostate cancer mortality [see comments]. Am J Epidemiol 137: 270-280, 1993
19. Dosemeci M, Hoover RN, Blair A, Figgs LW, Devesa S, Grauman D, Fraumeni JF Jr: Farming and prostate cancer among African-Americans in the southeastern United States. J Natl Cancer Inst 86: 1718-1719, 1994
20. Ekbom A, Hsieh CC, Lipworth L, Wolk A, Ponten J, Adam HO, Trichopoulos D: Perinatal characteristics in relation to incidence of and mortality from prostate cancer. Br Med J 313: 337-341, 1996
21. Whitmore WF Jr: Natural history of low-stage prostatic cancer and the impact of early detection. Urol Clin North Am 17: 689-697, 1990
22. Young HH: The early diagnosis and radical cure of carcinoma of the prostate; being a study of 40 cases and presentation of a radical operation which was carried out in 4 cases. Bull Johns Hopkins Hosp 16: 315-318, 1905
23. Lu-Yuo GL, Greenberg ER: Changes in prostate cancer incidence and treatment in USA [see comments]. Lancet 343: 251-254, 1994
24. Williams G: Radical prostatectomy in localised prostate cancer. In: Waxman J, Williams G (eds) Urological Oncology, London: Edward Arnold. 1992
25. Breslow N, Chan CE, Dhom G, Drury RAB, Frank LM, Gellei B, Lee YS, Lundberg S, Sparke B, Sternby NH, Tulinius H: Latent carcinoma of the prostate at autopsy in 7 areas. Int J Cancer 20: 680-688, 1996
26. Schroder FH: Detection of prostate cancer [editorial] [see comments]. Br Med J 310: 140-141, 1995
27. Ayala AG, Ro JY, Babaian R, Troncoso P, Grignon DJ: The prostatic capsule: does it exist? Its importance in the staging and treatment of prostatic carcinoma. Am J Surg Pathol 13: 21-27, 1989
28. McNeal JE: Normal histology of the prostate. Am J Surg Pathol 12: 619-633, 1988
29. McNeal JE, Bostwick DG: Anatomy of the prostate: implications for disease. In: Bostwick DG (ed) Pathology of the Prostate, pp. 1-14, New York: Churchill Livingstone. 1990
30. McNeal JE: Origin and development of carcinoma in the prostate. Cancer 23: 24-34, 1969
31. Allsbrook WC Jr, Simms WW: Histochemistry of the prostate [see comments]. [Review]. Hum Pathol 23: 297-305, 1992
32. Leong AS, Gilham P, Milos J: Cytokeratin and vimentin intermediate filament proteins in benign and neoplastic prostatic epithelium. Histopathology 13: 435-442, 1988
33. Ruizeveld de Winter JA, Janssen PJ, Sleddens HM, Verleun-Mooijman MC, Trapman J, Brinkmann AO, Santerse AR, Schroder FH, Van der Kwast TH: Androgen receptor status in localized and locally progressive hormone refractory human prostate cancer. Am J Pathol 144: 735-746, 1994
34. Cunha GR, Donjacour AA, Cooke PS, Mee S, Bigsby RM, Higgins SJ, Sugimura Y: The endocrinology and developmental biology of the prostate. [Review]. Endocr Rev 8: 338-362, 1987
35. Bonkhoff H, Stein U, Remberger K: Multidirectional differentiation in the normal, hyperplastic, and neoplastic human prostate: simultaneous demonstration of cell-specific epithelial markers. Hum Pathol 25: 42-46, 1994
36. Gown AM, Vogel AM: Monoclonal antibodies to human intermediate filament proteins: distribution of filament proteins in normal human tissues. Am J Pathol 114: 309-321, 1984
37. Hedrick L, Epstein JI: Use of keratin 903 as an adjunct in the diagnosis of prostate carcinoma. Am J Surg Pathol 13: 389-396, 1989
38. O'Malley FP, Grignon DJ, Shum DT: Usefulness of immunoperoxidase staining with high-molecular-weight cytokeratin in the differential diagnosis of small-acinar lesions of the prostate gland. Virchows Arch A Pathol Anat Histopathol 417: 191-196, 1990
39. Kramer CE, Epstein JI: Nucleoli in low-grade prostate adenocarcinoma and adenosis. Hum Pathol 24: 618-623, 1993
40. Collina G, Botticelli AR, Martinelli AM, Fano RA, Trentini GP: Sclerosing adenosis of the prostate. Report of 3 cases with electronmicroscopy and immunohistochemical study. Histopathology 20: 505-510, 1992
41. Kahane H, Sharp JW, Shuman GB, Dasilva G, Epstein JI: Utilization of high molecular weight cytokeratin on prostate needle biopsies in an independent laboratory. Urology 45: 981-986, 1995
42. Howat AJ, Mills PM, Lyons TJ, Stephenson TJ: Absence of S-100 protein in prostatic glands. Histopathology 13: 468-470, 1988
43. Srigley JR, Dardick I, Hartwick RW, Klotz LH: Basal epithelial cells of human prostate gland are not myoepithelial cells. A comparative immunohistochemical and ultrastructural study with human salivary gland. Am J Pathol 136: 957-966, 1990
44. Bonkhoff H, Remberger K: Widespread distribution of nuclear androgen receptor in the basal cell layer of the normal and hyperplastic human prostate. Virchows Arch A Pathol Anat Histopathol 422: 35-38, 1993
45. Chodak GW, Kranc DM, Puy LA, Takeda H, Johnson K, Chang C: Nuclear localization of androgen receptor in heterogeneous samples of normal, hyperplastic and neoplastic human prostate. J Urol 147: 798-803, 1992
46. Cohen RJ, Glezerson G, Taylor LF, Grundle HA, Naude JH: The neuroendocrine cell population of the human prostate gland. J Urol 150: 365-368, 1993
47. Abrahamsson PA, di Sant'Agnese PA: Neuroendocrine cells in the human prostate gland. [Review]. J Androl 14: 307-309, 1993
48. Aprikian AG, Cordon-Cardo C, Fair WR, Reuter VE: Characterization of neuroendocrine differentiation in human benign prostate and prostatic adenocarcinoma. Cancer 71: 3952-3965, 1993
49. di Sant'Agnese PA, de Mesy Jensen KL, Churukian CJ, Agarwal MM: Human prostatic endocrine-paracrine (APUD) cells. Distributional analysis with a comparison of serotonin and neuron-specific enolase immunoreactivity and silver stains. Arch Pathol Lab Med 109: 607-612, 1985
50. Davis NS, di Sant'Agnese PA, Ewing JF, Mooney RA: The neuroendocrine prostate: characterization and quantitation of calcitonin in the human gland. J Urol 142: 884-888, 1989
51. Bonkhoff H, Stein U, Remberger K: Androgen receptor status in endocrine-paracrine cell types of the normal, hyperplastic, and neoplastic human prostate. Virchows Arch A Pathol Anat Histopathol 423: 291-294, 1993
52. Noordzij MA, Van Steenbrugge GJ, Van der Kwast TH, Schroder FH: Neuroendocrine cells in the normal, hyperplastic and neoplastic prostate. [Review]. Urol Res 22: 333-341, 1995
53. di Sant'Agnese PA: Neuroendocrine differentiation in the precursors of prostate cancer. Eur Urol 30: 185-190, 1996
54. Kabalin JN, Peehl DM, Stamey TA: Clonal growth of human prostatic epithelial cells is stimulated by fibroblasts. Prostate 14: 251-263, 1989
55. Chung LW, Gleave ME, Hsieh JT, Hong SJ, Zhau HE: Reciprocal mesenchymal-epithelial interaction affecting prostate tumour growth and hormonal responsiveness. [Review]. Cancer Surv 11: 91-121, 1991
56. Cunha GR, Chung LWK, Sannon JM, Taguihi O, Fujii H: Hormone induced morphogenesis and growth: role of mesenchymal interactions. Recent Prog Horm Res 39: 559-598, 1993
57. Cunha GR, Chung LWK: Stromal epithelial interaction. Induction of prostate phenotype in urothelium of testicular feminized (TFm/y) mice. J Steroid Biochem 14: 1317-1312, 1981
58. Cunha GR: Epithelial stromal interactions in the development of the urogenital tract. Int Rev Cytol 47: 137-194, 1976
59. Bostwick DG: Is the behaviour of prostate cancer understood? In: Peeling WB (ed) Questions and Uncertainties about Prostate Cancer, pp. 30-49, Oxford: Blackwell Science. 1996
60. Bostwick DG: Progression of prostatic intraepithelial neoplasia to early invasive adenocarcinoma. Eur Urol 30: 145-152, 1996
61. Epstein JI, Grignon DJ, Humphrey PA, McNeal JE, Sesterhenn IA, Troncoso P, Wheeler TM: Interobserver reproducibility in the diagnosis of prostatic intraepithelial neoplasia. Am J Surg Pathol 19: 873-886, 1995
62. Raviv G, Janssen T, Zlotta AR, Descamps F, Verhest A, Schulman CC: Prostatic intraepithelial neoplasia: influence of clinical and pathological data on the detection of prostate cancer. J Urol 156: 1050-1055, 1996
63. Bostwick DG, Cooner WH, Denis L, Jones GW, Scardino PT, Murphy GP: The association of benign prostatic hyperplasia and cancer of the prostate. [Review]. Cancer 70: 291-301, 1992
64. Bostwick DG: High grade prostatic intraepithelial neoplasia (PIN): the most likely precursor of prostate cancer. Cancer 75: 1823-1836, 1993
65. Sakr WA, Haas GP, Cassin BF, Pontes JE, Crissman JD: The frequency of carcinoma and intraepithelial neoplasia of the prostate in young male patients [see comments]. J Urol 150: 379-385, 1993
66. Baretton GB, Vogt T, Blasenbreu S, Lohrs U: Comparison of DNA ploidy in prostatic intraepithelial neoplasia and invasive carcinoma of the prostate: an image cytometric study. Hum Pathol 25: 506-513, 1994
67. Crissman JD, Sakr WA, Hussein ME, Pontes JE: DNA quantitation of intraepithelial neoplasia and invasive carcinoma of the prostate. Prostate 22: 155-162, 1993
68. Weinberg DS, Weidner N: Concordance of DNA content between prostatic intraepithelial neoplasia and concomitant invasive carcinoma. Evidence that prostatic intraepithelial neoplasia is a precursor of invasive prostatic carcinoma. Arch Pathol Lab Med 117: 1132-1137, 1993
69. Arends MJ, Bird CC: Recombinant DNA technology and its diagnostic applications. Histopathology 21: 303-313, 1992
70. Crocker J: Molecular biology in histopathology. Chichester: John Wiley and Sons, 1994
71. Grody WW, Gatti RA, Naeim F: Diagnostic molecular pathology. Mod Pathol 2: 553-568, 1989
72. Rowley JD, Aster JC, Sklar J: The impact of new DNA diagnostic technology on the management of cancer patients. Survey of diagnostic techniques. Arch Pathol Lab Med 117: 1104-1109, 1993
73. Sklar J: DNA hybridization in diagnostic pathology. Hum Pathol 16: 654-658, 1985
74. Molecular techniques in diagnostic pathology. Hum Pathol 25: 555-614, 1994
75. Lee C, Shevrin DH, Kozlowski JM: In vivo and in vitro approaches to study metastasis in human prostatic cancer. [Review]. Cancer Metastasis Rev 12: 21-28, 1993
76. Isaacs JT, Isaacs WB, Feitz WW, Scheres J: Establishment and characterization of seven Dunning rat prostatic cancer cell lines and their use in developing methods for predicting metastatic abilities of prostatic cancers. Prostate 9: 261-281, 1986
77. Hedlund TE, Moffatt KA, Miller GJ: Stable expression of the nuclear vitamin D receptor in the human prostatic carcinoma cell line JCA-1: evidence that the antiproliferative effects of 1 alpha, 25-dihydroxyvitamin D3 are mediated exclusively through the genomic signaling pathway. Endocrinology 137: 1554-1561, 1996
78. Naghashfar Z, DiPaolo JA, Woodworth CD, Passaniti A: Immortalization of human adult prostatic adenocarcinoma cells by human papilloma virus HPV16 and -18 DNA. Cancer Lett 100: 47-54, 1996
79. Horoszewicz JS, Leong SS, Kawinski E, Karr JP, Rosenthal H, Chu TM, Mirand EA, Murphy GP: LNCaP model of human prostatic carinoma. Cancer Res 43: 1909-1818, 1983
80. Murakami YS, Albertsen H, Brothman AR, Leach RJ, White RL: Suppression of the malignant phenotype of human prostatic cancer cell line PPC-1 by introduction of normal fragments of human chromosome 10. Cancer Res 56: 2157-2160, 1996
81. Hurkadli KS, Lokeshwar B, Sheth AR, Block NL: Detection of prostatic-inhibin-like peptide in the cytoplasm of LNCaP cells, a human prostatic adenocarcinoma cell line. Prostate 24: 285-290, 1994
82. Israeli RS, Powell CT, Corr JG, Fair WR, Heston WD: Expression of the prostate-specific membrane antigen. Cancer Res 54: 1807-1811, 1994
83. Furr BJ, Tucker H: The preclinical development of bicalutamide: pharmacodynamics and mechanism of action Urology 47: 13-25: discussion 29-32, 1996
84. Taplin M-E, Bubley GJ, Shuster TD, Frantz ME, Spooner AE, Ogata GK, Keer HN, Balk SP: Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N Engl J Med 332: 1393-1398, 1995
85. Lee C, Shevrin DH, Kozlowski JM. In vivo and in vitro approaches to study metastasis in human prostatic cancer [Review]. Cancer Metastasis Rev 12: 21-28, 1993
86. Kaighn ME, Narayan KS, Ohnuki Y, Lechner JF, Jones LW: Establishment and characterization of a human prostatic carcinoma cell line (PC-3). Invest Urol 17: 16-23, 1979
87. Garde SV, Sheth AR, Porter AT, Pienta KJ: A comparative study on expression of prostatic inhibin peptide, prostate acid phosphatase and prostate specific antigen in androgen independent human and rat prostate carcinoma cell lines. Cancer Lett 70: 159-166, 1993
88. Stearns ME, Wang M, Stearns M: IL-10 blocks collagen IV invasion by 'invasion stimulating factor' activated PC-3 ML cells: upregulation of TIMP-1 expression. Oncol Res 7: 157-163, 1995
89. Bishop JM: Molecular themes in oncogenesis. Cell 64: 235-248, 1996
90. Lisitsyn N, Wigler M: Cloning the differences between 2 complex genomes. Science 259: 946-951, 1993
91. Dong JT, Lamb PW, Rinker-Schaeffer CW, Vukanovic J, Ichikawa T, Isaacs JT, Barrett JC: KAI1, a metastasis suppressor gene for prostate cancer on human chromosome 11p11.2. Science 268: 884-886, 1995
92. Berthon P, Dimitrov T, Stower M, Cussenot O, Maitland NJ: A microdissection approach to detect molecular markers during progression of prostate cancer. Br J Cancer 72: 946-951, 1995
93. Innis MA, Gelfand GH, Sninsky JJ, White TJ: PCR protocols, a guide to methods and applications. San Diego, California: Academic Press, 1990
94. Jackson V: Studies on histone organization in the nucleosome using formaldehyde as a reversible cross-linking agent. Cell 15: 945-954, 1978
95. Yasui W, Ito H, Tahara E: DNA analysis of archival material and its application to tumour pathology. Diagnostic molecular pathology. A practical approach. Oxford: IRL Press, 1992
96. Eisenberg M, Chimera JA: Human identification by DNA analysis. Diagnostic molecular pathology. A practical approach. Oxford: IRL Press, 1992
97. Orita M, Suzuki Y, Sekiya T, Hayashi K: Rapid and sensitive detection of point mutations and DNA polymorphisms using the polymerase chain reaction. Genomics 5: 874-879, 1989
98. Orita M, Iwahana H, Kanazawa H, Hayashi K, Sekiya T: Detection of polymorphisms of human DNA by gel electrophoresis as single-strand conformation polymorphisms. Proc Natl Acad Sci USA 86: 2766-2770, 1989
99. Gall JG, Pardue ML: Formation and detection of RNA-DNA hyrid molecules in cytological preparations. Proc Natl Acad Sci USA 63: 378-383, 1969
100. Herrington S, McGee JO: Diagnostic molecular pathology: A practical approach. In: Herrington CS, McGee JO (eds) Principles and Basic Methodology of DNA/RNA Detection by in situ Hybridization, pp. 69-102, Oxford: IRL Press, 1992
101. Trent JM: Clinical correlations of chromosome change in human solid minors: the lip of the iceberg? J Natl Cancer Inst 81: 1874-1878, 1989
102. Sandberg AA, Turc-Carel C, Gemmill RM: Chromosomes in solid tumors and beyond. Cancer Res 48: 1049-1059, 1988
103. Morrison L, Legator M: Multicolor in situ hybridisation using direct labelled fluorescent probes. Clin Chem 39: 733-734, 1993
104. Alcaraz A, Takahashi S, Brown JA, Herath JF, Bergstralh EJ, Larson-Keller JJ, Lieber MM, Jenkins RB: Aneuploidy and aneusomy of chromosome 7 detected by fluorescence in situ hybridization arc markers of poor prognosis in prostate cancer. Cancer Res 54: 3998-4002, 1994
105. Mullis KB, Faloona FA: Specific synthesis of DNA in vitro via a polymerase-catalyzed chain reaction. Methods Enzymol 155: 335-350, 1987
106. McPherson MJ, Quirke P, Taylor GR (eds): PCR. A practical approach. Oxford: IRL Press, 1991
107. Brothman AR, Peehl DM, Patel AM, McNeal JE: Frequency and pattern of karyotypic abnormalities in human prostate cancer. Cancer Res 50: 3795-3803, 1990
108. Konig JJ, Teubel W, Van Dongen JW, Hagemeijer A, Romijn JC, Schroder FH: Tissue culture loss of aneuploid cells from carcinomas of the prostate. Genes Chromosom Cancer 8: 22-27, 1993
109. Micale MA, Mohamed A, Sakr W, Powell IJ, Wolman SR: Cytogenetics of primary prostatic adenocarcinoma. Clonality and chromosome instability. Cancer Genet Cytogenet 61: 165-173, 1992
110. Bandyk MG, Zhao L, Troncoso P, Pisters LL, Palmer JL, von Eschenbach AC, Chung LW, Liang JC: Trisomy 7: a potential cytogenetic marker of human prostate cancer progression. Genes Chromosom Cancer 9: 19-27, 1994
111. Takahashi S, Shan AL, Ritland SR, Delacey KA, Bostwick DG, Lieber MM, Thiobideau SN, Jenkins RB: Frequent loss of heterozygosity at 7q31.1 in primary prostate cancer is associated with tumor aggressiveness and progression. Cancer Res 55: 4114-4119, 1995
112. Carter BS, Ewing CM, Ward WS, Treiger BF, Aalders TW, Schalken JA, Epstein JI, Isaacs WB: Allelic loss of chromosomes 16q and 10q in human prostate cancer. Proc Natl Acad Sci USA 87: 8751-8755, 1990
113. Kunimi K, Bergerheim US, Larsson IL, Ekman P, Collins VP: Allelotyping of human prostatic adenocarcinoma. Genomics 11: 530-536, 1991
114. Bergerheim US, Kunimi K, Collins VP, Ekman P: Deletion mapping of chromosomes 8, 10, and 16 in human prostatic carcinoma. Genes Chromosom Cancer 3: 215-220, 1991
115. Bova GS, Carter BS, Bussemakers MJ, Emi M, Fujiwara Y, Kyprianou N, Jacobs SC, Robinson JC, Epstein JI, Walsh PC et al.: Homozygous deletion and frequent allelic loss of chromosome 8p22 loci in human prostate cancer. Cancer Res 53: 3869-3873, 1993
116. MacGrogan D, Levy A, Bostwick D, Wagner M, Wells D, Bookstein R: Loss of chromosome arm 8p loci in prostate cancer: mapping by quantitative allelic imbalance. Genes Chromosom Cancer 10: 151-159, 1994
117. Macoska JA, Trybus TM, Sakr WA, Wolf MC, Benson PD, Powell IJ, Pontes JE: Fluorescence in situ hybridization analysis of 8p allelic loss and chromosome 8 instability in human prostate cancer. Cancer Res 54: 3824-3830, 1994
118. Vocke CD, Pozzatti RO, Bostwick DG, Florence CD, Jennings SB, Srup SE, Duray PH: Analysis of 99 microdissected prostate carcinomas reves a high frequency of allelic loss on chromosome 8p 12-21. Cancer Res 56: 24111-24126, 1996
119. Emmert-Buck MR, Vocke CD, Pozzatti RO, Duray PH, Jennings SB, Florence CD, Zhuang Z, Bostwick DG, Liotta LA, Linehan WM: Allelic loss on chromosome 8p12-21 in microdissected prostatic intraepithelial neoplasia. Cancer Res 55: 2959-2962, 1995
120. Trapman J, Sleddens HF, Van der Weiden MM, Dinjens WN, Konig JJ, Schroder FH, Faber PW, Bosman FT: Loss of heterozygosity of chromosome 8 microsatellite loci implicates a candidate tumor suppressor gene between the loci D8S87 and D8S133 in human prostate cancer. Cancer Res 54: 6061-6064, 1994
121. Brothman AR, Patel AM: Characterization of 10 marker chromosomes in a prostatic cancer cell line by in situ hybridization. Cytogenet Cell Genet 60: 8-11, 1992
122. Murakami YS, Albertsen H, Brothman AR, Leach RJ, White RL: Suppression of the malignant phenotype of human prostate cancer cell line PPC-1 by introduction of normal fragments of human chromosome 10. Cancer Res 56: 2157-2160, 1996
123. Deitch AD, De Vere White RW: Flow cytometry as a predictive modality in prostate cancer. [Review]. Hum Pathol 23: 352-359, 1992
124. Tribukait B: Flow cytometry in assessing the clinical aggressiveness of genito-urinary neoplasms. World J Urol 5: 108-122, 1996
125. Falkmer UG: Methodologie sources of errors in image and flow cytometric DNA assessments of the malignancy potential of prostatic carcinoma. [Review]. Hum Pathol 23: 360-367, 1992
126. Jones EC, McNeal J, Bruchovsky N, De Jong G: DNA content in prostatic adenocarcinoma. A flow cytometry study of the predictive value of aneuploidy for tumor volume, percentage Gleason grade 4 and 5, and lymph node metastases. Cancer 66: 752-757, 1990
127. Bos JL: Ras oncogenes in human prostate: review. Cancer Res 49: 4682-4689, 1989
128. Barbacid M: Ras oncogenes: their role in neoplasia. Eur J Clin Invest 20: 225-235, 1990
129. Peehl DM: Oncogenes in prostate cancer. An update. [Review]. Cancer 71: 1159-1164, 1993
130. McCormick F: Activators and effectors of ras p21 proteins. Curr Opin Genet.Dev 4: 71-76, 1994
131. Pergolizzi RG, Kreis W, Rottach C, Susin M, Broome JD: Mutational status of codons 12 and 13 of the N- and K-ras genes in tissue and cell lines derived from primary and metastatic prostate carcinomas [see comments]. Cancer Invest 11: 25-32, 1993
132. Peehl DM, Wehner N, Stamey TA: Activated Ki-ras oncogene in human prostatic adenocarcinoma. Prostate 10: 281-289, 1987
133. Tsujii T, Yonese J, Kojima S, Tari K, Ishii M, Seino Y: [The clinical usefulness of urinary basic fetoprotein (BFP) in patients with urological malignancies]. [Japanese]. Nippon Hinyokika Gakkai Zasshi 81: 829-834, 1990
134. Gumerlock PH, Poonamallee UR, Meyers FJ, De Vere White RW: Activated ras alleles in human carcinoma of the prostate are rare. Cancer Res 51: 1632-1637, 1991
135. Konishi N, Enomoto T, Buzard G, Ohshima M, Ward JM, Rice JM: K-ras activation and ras p21 expression in latent prostatic carcinoma in Japanese men. Cancer 69: 2293-2299, 1992
136. Anwar K, Nakakuki K, Shiraishi T, Naiki H, Yatani R, Inuzuka M: Presence of ras oncogene mutations and human papillomavirus DNA in human prostate carcinomas. Cancer Res 52: 5991-5996, 1992
137. Moul, Theune SM, Chang EH: Detection of ras mutations in archival testicular germ cell tumours by polymerase chain reaction and oligonucleotide hybridization. Genes Chromosom Cancer 5: 109-118, 1992
138. Voeller HJ, Wilding G, Gelmann EP: v-rasH expression confers hormone-independent in vitro growth to LNCaP prostate carcinoma cells. Mol Endocrinol 5: 209-216, 1991
139. Treiger B, Isaacs J: Expression of a transfected v-Harvey-ras oncogene in a Dunning rat prostate adenocarcinoma and the development of high metastatic ability. J Urol 140: 1580-1586, 1988
140. Schalken JA, Ebeling SB, Isaacs JT, Treiger B, Bussemakers MJ, de Jon ME, Van de Ven WJ: Down modulation of fibronectin messenger RNA in metastasizing rat prostatic cancer cells revealed by differential hybridization analysis. Cancer Res 48: 2042-2046, 1988
141. Partin AW, Isaacs JT, Treiger B, Coffey DS: Early cell motility changes associated with an increase in metastatic ability in rat prostatic cancer cells transfected with the v-Harvey-ras oncogene. Cancer Res 48: 6050-6053, 1988
142. Carter BS, Epstein JI, Isaacs WB: Ras gene mutations in human prostate cancer. Cancer Res 50: 6830-6832, 1990
143. Viola MV, Fromowitz F, Oravez S, Deb S, Finkel G, Lundy J, Hand P, Thor A, Schlom J: Expression of ras oncogene p21 in prostate cancer. N Engl J Med 314: 133-137, 1986
144. Sumiya H, Masai M, Akimoto S, Yatani R, Shimazaki J: Histochemical examination of expression of ras p21 protein and R 1881-binding protein in human prostatic cancers. Eur J Cancer 26: 786-789, 1990
145. Varma VA, Austin GE, O'Connell AC: Antibodies to ras oncogene p21 proteins lack immunohistochemical specificity for neoplastic epithelium in human prostate tissue. Arch Pathol Lab Med 113: 16-19, 1989
146. Bussemakers MJ, Isaacs JT, Debruyne FMJ, Van der Ven WJM. Schalken JA: Oncogene expression in prostate cancer. World J Urol 9: 58-63, 1991
147. Cooke DB, Quarmby VE, Petrusz P, Mickey DD, Der CJ, Isaacs JT, French FS: Expression of ras proto-oncogenes in the Dunning R3327 rat prostatic adenocarcinoma system. Prostate 13: 273-287, 1988
148. Kato GJ, Barret J, Villa Garcia M, Dang C: An amino terminal c-myc domain required for neoplastic transformation activates transcription. Mol Cell Biol 10: 5914-5920, 1990
149. Escort C, Theillet C, Lidereau R, Spyratos F, Champeme MH, Gest M, Callahan R: Genetic alterations of the c-myc proto-oncogene in human primary breast carcinoma. Proc Natl Acad Sci USA 83: 4834, 1986
150. Fleming WH, Hamel A, MacDonald R, Ramsey E, Pettigrew NM, Johnston B, Dodd JG, Matusik RJ: Expression of the c-myc protooncogene in human prostatic carcinoma and benign prostatic hyperplasia. Cancer Res 46: 1535-1538, 1986
151. Phillips ME, Ferro MA, Smith PJ, Davies P: Intranuclear androgen receptor deployment and protooncogene expression in human diseased prostate. Urol Int 42: 115-119, 1987
152. Buttyan R, Sawczuk IS, Benson MC, Siegal JD, Olsson CA: Enhanced expression of the c-myc protooncogene in high-grade human prostate cancers. Prostate 11: 327-337, 1987
153. Cooke DB, Quarmby VE, Mickey DD, Isaacs JT, French FS: Oncogene expression in prostate cancer: Dunning R3327 rat dorsal prostatic adenocarcinoma system. Prostate 13: 263-272, 1988
154. Eaton CL, Davies P, Phillips ME: Growth factor involvement and oncogene expression in prostatic tumours. J Steroid Biochem 30: 341-345, 1988
155. Matusik RJ, Fleming WH, Hamel A, Westenbrink TG, Hrabarchuk B, MacDonald R, Ramsey E, Gartner JG, Pettigrew NM, Johnston B et al.: Expression of the c-myc proto-oncogene in prostatic tissue. [Review]. Prog Clin Biol Res 239: 91-112, 1987
156. Funa K, Nordgren H, Nilsson S: In situ expression of mRNA for proto-oncogenes in benign prostatic hyperplasia and in prostatic carcinoma. Scand J Urol Nephrol 25: 95-100, 1991
157. Thompson TC, Southgate J, Kitchener G, Land H: Multistage carcinogenesis induced by ras and myc oncogenes in a reconstituted organ. Cell 56: 917-930, 1989
158. Carter HB, Piantadosi S, Isaacs JT: Clinical evidence for an implications of the multistep development of prostate cancer. J Urol 143: 742-746, 1990
159. Hynes NE, Gerber HA, Saurer S, Groner B: Overexpression of the c-erbB-2 protein in human breast tumor cell lines. J Cell Biochem 39: 167-173, 1989
160. King CR, Kraus MH, Aaronson SA: Amplification of a novel v-erbB-related gene in a human mammary carcinoma. Science 229: 974-976, 1985
161. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235: 177-182, 1987
162. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A et al.: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244: 707-712, 1989
163. Zhau HE, Wan DS, Zhou J, Miller GJ, von Eschenbach AC: Expression of c-erb B-2/neu proto-oncogene in human prostatic cancer tissues and cell lines. Mol Carcinog 5: 320-327, 1992
164. Ware JL, Maygarden SJ, Koontz WW Jr, Strom SC: Immunohistochenmical detection of c-erbB-2 protein in human benign and neoplastic prostate. Hum Pathol 22: 254-258, 1991
165. Mellon K, Thompson S, Charlton RG, Marsh C, Robinson M, Lane DP, Harris AL, Home CH, Neal DE: p53, c-erbB-2 and the epidermal growth factor receptor in the benign and malignant prostate. J Urol 147: 496-499, 1992
166. Visakorpi T, Kallioniemi OP, Koivula T, Harvey J, Isola J: Expression of epidermal growth factor receptor and ERBB2 (HER-2/Neu) oncoprotein in prostatic carcinomas. Mod Pathol 5: 643-648, 1992
167. Sadasivan R, Morgan R, Jennings S, Austenfeld M, Van Veldhuizen P, Stephens R, Noble M: Overexpression of Her-2/neu may be an indicator of poor prognosis in prostate cancer. J Urol 150: 126-131, 1993
168. Kuhn EJ, Kurnot RA, Sesterhenn IA, Chang EH, Moul JW: Expression of the c-erbB-2 (HER-2/neu) oncoprotein in human prostatic carcinoma. [Review]. J Urol 150: 1427-1433, 1993
169. Klotz LH, Auger M, Andrulis I, Srigley J: Molecular analysis of neu, sis, c-myc, fos, and P53 oncogenes in benign prostatic hypertrophy and prostatic carcinoma. J Urol 143: 401A, 1990
170. Grob MB, Schellhammer PF, Wright GL et al.: Expression of the c-erbB2 oncogene in human prostatic carcinoma. J Urol 145: 294A, 1991
171. Smith RG, Nag AL: Regulation of c-sis expression in tumors of the male reproductive tract. [Review]. Prog Clin Biol Res 239: 113-122, 1987
172. Rijnders AW, Van der Korput JA, Van Steenbrugge GJ, Romijn JC, Trapman J: Expression of cellular oncogenes in human prostatic carcinoma cell lines Biochem Biophys Res Commun 132: 548-554, 1985
173. Davies P, Eaton CL, France TD, Phillips ME: Growth factor receptors and oncogene expression in prostate cells. [Review]. Am J Clin Oncol 11 Suppl 2: S1-7, 1988
174. McDonnell TJ, Troncoso P, Brisbay SM, Logothetis CJ, Chung LK, Hsieh JT: Bcl-2 expression in androgen-independent prostate carcinoma. J Urol 149: 221A, 1993
175. Raffo AJ, Perlman H, Chen MW, Day ML, Streitman JS, Buttyan R: Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo. Cancer Res 55: 4438-4445, 1995
176. Fearon ER, Vogelstein BA: A genetic model forcolorectal tumorigenesis. Cell 61: 759-769, 1990
177. Seemayer TA, Cavence WK: Biology of disease: molecular mechanisms of oncogenesis. Lab Invest 60: 585-599, 1989
178. Marshall CJ: Tumor suppressor genes. Cell 64: 313-326, 1991
179. Weinberg RA: Tumor suppressor genes. Science 254: 249-270, 1991
180. Romas NA, Kwan DJ: Prostatic acid phosphatase. Biomolecular features and assays for serum determination. [Review]. Urol Clin North Am 20: 581-588, 1993
181. Nigro JM, Baker SJ, Preisinger AC, Jessup JM, Hostetter R, Cleary K, Bigner SH, Davidson N, Baylin S, Devilee P et al.: Mutations in the p53 gene occur in diverse human tumour types. Nature 342: 705-708, 1989
182. Hollstein M, Sidransky D, Vogelstein B, Harris CC: p53 mutations in human cancers. [Review]. Science 253: 49-53, 1991
183. Malkin D, Li FP, Strong LC, Fraumeni J Jr, Nelson CE, Kim DH, Kassel J, Gryka MA, Bischoff FZ, Tainsky MA, Friend SH: Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas and other neoplasms. Science 250: 1233-1238, 1990
184. Frebourg T, Friend SH: Cancer risks from germ-line p53 mutations. J Clin Invest 90: 1637-1641, 1992
185. Friend SH, Horowitz JM, Gerber MR, Wang XF, Bogenmann E, Li FP, Weinberg RA: Deletions of a DNA sequence in retinoblastomas and mesenchymal tumors: organization of the sequence and its encoded protein [published erratum appears in Proc Natl Acad Sci USA 1988 Apr; 85 (7): 2234]. Proc Natl Acad Sci USA 84: 9059-9063, 1987
186. Mendoza AE, Shew JY, Lee EY, Bookstein R, Lee WH: A case of synovial sarcoma with abnormal expression of the human retinoblastoma susceptibility gene. Hum Pathol 19: 487-489, 1988
187. Harbour JW, Lai SL, Whang-Peng J, Gazdar AF, Minna JD, Kaye FJ: Abnormalities in structure and expression of the human retinoblastoma gene in SCLC. Science 241: 353-357, 1988
188. T'Ang A, Varley JM, Chakraborty S, Murphree AL, Fung YK: Structural rearrangement of the retinoblastoma gene in human breast carcinoma., Science 242: 263-266, 1988
189. Yokota J, Akiyama T, Fung YK, Benedict WF, Namba Y, Hanaoka M, Wada M, Terasaki T, Shimosato Y, Sugimura T et al.: Altered expression of the retinoblastoma (RB) gene in small-cell carcinoma of the lung. Oncogene 3: 471-475, 1988
190. Varley JM, Armour J, Swallow JE, Jeffreys AJ, Ponder BA, T'Ang A, Fung
191. Bookstein R, Shew JY, Chen PL, Scully P, Lee WH: Suppression of tumorigenicity of human prostate carcinoma cells by replacing a mutated RB gene. Science 247: 712-715, 1990
192. Bookstein R, Rio P, Madreperla SA, Hong F, Allred C, Grizzle WE, Lee WH: Promoter deletion and loss of retinoblastoma gene expression in human prostate carcinoma. Proc Natl Acad Sci USA 87: 7762-7766, 1990
193. Brooks JD, Bova GS, Isaacs WB: Allelic loss of the retinoblastoma gene in primary human prostatic adenocarcinomas. Prostate 26: 35-39, 1995
194. Donehower LA, Bradeley A: The tumor suppressor gene p53, Biochim Biophys Acta 1155: 181-205, 1993
195. Levine AJ: The TSGs. Ann Rev Biochem 621: 623-651, 1993
196. Harris CC, Hollstein M: Clinical implications of the p53 tumor-suppressor gene [see comments]. [Review]. N Engl J Med 329: 1318-1327, 1993
197. Takahashi T, Suzuki H, Hida T, Sekido Y, Ariyoshi Y, Ueda R: The p53 gene is very frequently mutated in small-cell lung cancer with a distinct nucleotide substitution pattern. Oncogene 6: 1775-1778, 1991
198. Sidransky D, von Eschenbach A, Tsai YC, Jones P, Summerhayes I, Marshall F, Paul M, Green P, Hamilton SR, Frost P et al.: Identification of p53 gene mutations in bladder cancers and urine samples. Science 252: 706-709, 1991
199. Visakorpi T, Kallioniemi OP, Heikkinen A, Koivula T, Isola J: Small subgroup of aggressive, highly proliferative prostatic carcinomas defined by p53 accumulation. J Natl Cancer Inst 84: 883-887, 1992
200. Bookslein R, MacGrogan D, Hilsenbeck SG, Sharkey F, Allred DC: p53 is mutated in a subset of advanced-stage prostate cancers. Cancer Res 53: 3369-3373, 1993
201. Dinjens WN, Van der Weiden MM, Schroeder FH, Bosman FT, Trapman J: Frequency and characterization of p53 mutations in primary and metastatic human prostate cancer. Int J Cancer 56: 630-633, 1994
202. Voeller HJ, Sugars LY, Pretlow T, Gelmann EP: p53 oncogene mutations in human prostate cancer specimens. J Urol 151: 492-495, 1994
203. Navone NM, Troncoso P, Pisters LL, Goodrow TL, Palmer JL, Nichols WW, von Eschenbach AC, Conti CJ: p53 protein accumulation and gene mutation in the progression of human prostate carcinoma. J Natl Cancer Inst 85: 1657-1669, 1993
204. Effert PJ, McCoy RH, Walther PJ, Liu ET: p53 gene alterations in human prostate carcinoma. J Urol 150: 257-261, 1993
205. Aprikian AG, Sarkis AS, Fair WR, Zhang ZF, Fuks Z, Cordon-Cardo C: Immunohistochemical determination of p53 protein nuclear accumulation in prostatic adenocarcinoma. J Urol 151: 1276-1280, 1994
206. Evans RM: The steroid and thyroid hormone receptor superfamily. Science 240: 889-895, 1988
207. Brinkmann AO, Kuiper GG, Ris-Stalpers C, Van Rooij HC, Romalo G, Trifiro M, Mulder E, Pinsky L, Schweikert HU, Trapman J: Androgen receptor abnormalities. [Review]. J Steroid Biochem Mol Biol 40: 349-352, 1991
208. Faber PW, Van Rooij HCJ, Schipper HP, Brinkmann AO, Trapman J: Two different, overlapping pathways of transcription initiation are active on the TAT-less human androgen receptor promoter. J Biol Chem 268: 9296-9301, 1993
209. Rundlett SE, Wu XP, Miesfeld RL: Functional characterizations of the androgen receptor confirm that the molecular basis of androgen action is transcriptional regulation. Mol Endocrinol 4: 708-714, 1990
210. Jenster G, Van der Korput HA, Van Vroonhoven C, Van der Kwast TH, Trapman J, Brinkmann AO: Domains of the human androgen receptor involved in steroid binding, transcriptional activation, and subcellular localization. Mol Endocrinol 5: 1396-1404, 1991
211. Luisi BF, Xu WX, Otwinowski Z, Feedman LP, Yamamoto KR, Sigler PB: Crystallographic analysis of the interaction of the glucocorticoid receptor with DNA. Nature 352: 497-505, 1991
212. Picard D, Kumar V, Chambon P, Yamamoto KR: Signal transduction by steroid hormones: nuclear localization is differentially regulated in estrogen and glucocorticoid receptors. Cell Regul 1: 291-299, 1990
213. Tilley WD, Wilson CM, Marcelli M, McPhaul MJ: Androgen receptor gene expression in human prostate carcinoma cell lines. Cancer Res 50: 5382-5386, 1990
214. Visakorpi T, Hyytinen E, Koivisto P, Tanner M, Keinanen R, Palmberg C, Palotie A, Tammela T, Isola J, Kallioniemi OP: in vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat Genet 9: 401-406, 1995
215. Klocker H, Culig Z, Kaspar F, Hobisch A, Eberle J, Reissigl A, Bartsch G: Androgen signal transduction and prostatic carcinoma. [Review]. World J Urol 12: 99-103, 1994
216. Barrack ER, Bujnovsky P, Walsh PC: Subcellular distribution of androgen receptors in benign hyperplastic and malignant prostatic tissues: characterisation of salt resistant receptors. Cancer Res 43: 1107-1116, 1983
217. Kyprianou N, Davies P: Association states of androgen receptor nuclei of human benign hypertrophic prostate. Prostate 8: 363-380, 1986
218. Ekman P, Brolin J: Steroid receptor profile in human prostate cancer metastases as compared with primary prostatic carcinoma. Prostate 18: 147-153, 1991
219. Masai M, Sumiya H, Akimoto S, Yatani R, Chang CS, Liao SS, Shimazaki J: Immunohistochemical study of androgen receptor in benign hyperplastic and cancerous human prostates. Prostate 17: 293-300, 1990
220. Suzuki H, Sato N, Watabe Y, Masai M, Seino S, Shimazaki J: Androgen receptor gene mutations in human prostate cancer. J Steroid Biochem Mol Biol 46: 759-765, 1993
221. Newmark JR, Hardy DO, Tonb DC, Carter BS, Epstein JI, Isaacs WB, Brown TR, Barrack ER: Androgen receptor gene mutations in human prostate cancer. Proc Natl Acad Sci USA 89: 6319-6323, 1992
222. Gaddipati JP, McLeod DG, Heidenberg HB, Sesterhenn IA, Finger MJ, Moul JW, Srivastava S: Frequent detection of codon 877 mutation in the androgen receptor gene in advanced prostate cancers. Cancer Res 54: 2861-2864, 1994
223. Edwards A, Hammond HA, Jin L, Caskey CT, Chakraborty R: Genetic variation of five trimeric and tetrameric tandem repeal loci in four human population groups. Genomics 12: 241-253, 1992
224. Sleddens HF, Oostra BA, Brinkmann AO et al.: Tyrinucleotide (GGN) repeat polymorphism in the human androgen receptor. Hum Mol Genet 2: 273, 1993
225. Chamberlin NL, Driver ED, Miesfield RL: The length and location of CAG trinucleotide repeats in the androgen receptor N-terminal domain effect transactivation function. Nucleic Acids Res 22: 3181-3186, 1994
226. Irvine RA, Yu MC, Ross RK, Coetzee GA: The CAG and GGC microsatellites of the androgen receptor gene are in linkage disequilibrium in men with prostate cancer. Cancer Res 55: 1937-1940, 1995
227. Schoenberg MP, Hakimi JM, Wang S, Bova GS, Epstein JI, Fischbeck KH, Isaacs WB, Walsh PC, Barrack ER: Microsatellite mutation (CAG24→18) in the androgen receptor gene in human prostate cancer. Biochem Biophys Res Commun 198: 74-80, 1994
228. Byrne RL, Leung H, Neal DE: Peptide growth factors in the prostate as mediators of stromal epithelial interactions Br J Urol 77: 627-633, 1996
229. Norgaard P, Hougaard S, Poulsen HS, Spang-Thomsen M: Transforming growth factor beta and cancer. [Review]. Cancer Treat Rev 21: 367-403, 1995
230. Kim IY, Ahn HJ, Zelner DJ, Shaw JW, Sensibar JA, Kim JH, Kato M, Lee C: Genetic change in transforming growth factor beta (TGF-beta) receptor type I gene correlates with insensitivity to TGF-beta 1 in human prostate cancer cells. Cancer Res 56: 44-48, 1996
231. Goldstein D, O'Leary M, Mitchen J, Borden EC, Wilding G: Effects of interferon beta ser and transforming growth factor beta on prostatic cell ines. J Urol 146: 1173-1177, 1991
232. Zentella A, Weis FM, Ralph DA, Laiho M, Massague J: Early gene responses to transforming growth factor-beta in cells lacking growth-suppressive RB function. Mol Cell Biol 11: 4952-4958, 1991
233. Truong LD, Kadmon D, McCune BK, Flanders KC, Scardino PT, Thompson TC: Association of transforming growth factor-beta 1 with prostate cancer: an immunohistochemical study. Hum Pathol 24: 4-9, 1993
234. Ivanovic V, Melman A, Davis-Joseph B, Valcic M, Geliebter J: Elevated plasma levels of TGF-beta 1 in patients with invasive prostate cancer [letter]. Nature Med 1: 282-284, 1995
235. Morton DM, Barrack ER: Modulation of transforming growth factor beta 1 effects on prostate cancer cell proliferation by growth factors and extracellular matrix. Cancer Res 55: 2596-2602, 1995
236. Steiner MS, Barrack ER: Transforming growth factor-beta 1 overproduction in prostate cancer: effects on growth in vivo and in vitro. Mol Endocrinol 6: 15-25, 1992
237. Wilding G, Zugmeier G, Knabbe C, Flanders K, Gelmann E: Differential effects of transforming growth factor beta on human prostate cancer cells in vitro. Mol Cell Endocrinol 62: 79-87, 1989
238. Desruisseau, Ghazarossian Ragni E, Chinot O, Martin PM: Divergent effect of TGFbeta1 on growth and proteolytic modulation of human prostatic cancer cell lines. Intern J Cancer 66: 796-801, 1996
239. Cooney KA, Wetzel JC, Merajver SD, Macoska JA, Singleton TP, Wojno KJ: Distinct regions of allelic loss on 13q in prostate cancer. Cancer Res 56: 1142-1145, 1996
240. Lloyd SN, Brown LL, Leake RE: Transforming growth factor-alpha expression in benign and malignant human prostatic disease. Int J Biol Markers 7: 27-34, 1992
241. Ching KZ, Ramsey E, Pettigrew N, D'Cunha R, Jason M, Dodd JG: Expression of mRNA for epidermal growth factor, transforming growth factor-alpha and their receptor in human prostate tissue and cell lines. Mol Cell Biochem 126: 151-158, 1993
242. Morris GL, Dodd JG: Epidermal growth factor receptor mRNA levels in human prostatic tumors and cell lines. J Urol 143: 1272-1274, 1990
243. Fox SB, Persad RA, Coleman N, Day CA, Silcocks PB, Collins CC: Prognostic value of c-erbB-2 and epidermal growth factor receptor in stage A1 (T1a) prostatic adenocarcinoma. Br J Urol 74: 214-220, 1994
244. Connolly JM, Rose DP: Secretion of epidermal growth factor and related polypeptides by the DU 145 human prostate cancer cell line. Prostate 15: 177-186, 1989
245. Connolly JM, Rose DP: Autocrine regulation of DU145 human prostate cancer cell growth by epidermal growth factor-related polypeptides. Prostate 19: 173-180, 1991
246. Hofer DR, Sherwood ER, Bromberg WD, Mendelsohn J, Lee C, Kozlowski JM: Autonomous growth of androgen-independent human prostatic carcinoma cells: role of transforming growth factor alpha. Cancer Res 51: 2780-2785, 1991
247. Connolly JM, Rose DP: Production of epidermal growth factor and transforming growth factor-alpha by the androgen-responsive LNCaP human prostate cancer cell line. Prostate 16: 209-218, 1990
248. Liu XH, Wiley HS, Meikle AW: Androgens regulate proliferation of human prostate cancer cells in culture by increasing transforming growth factor-alpha (TGF-alpha) and epidermal growth factor (EGF)/TGF-alpha receptor. J Clin Endocrinol Metab 77: 1472-1478, 1993
249. Schuurmans AL, Bolt J, Mulder E: Androgens stimulate both growth rate and epidermal growth factor receptor activity of the human prostate tumor cell LNCaP. Prostate 12: 55-63, 1988
250. Brass AL, Barnard J, Patai BL, Salvi D, Rukstalis DB: Androgen up-regulates epidermal growth factor receptor expression and binding affinity in PC3 cell lines expressing the human androgen receptor. Cancer Res 55: 3197-3203, 1995
251. Xie H, Turner T, Wang MH, Singh RK, Siegal GP, Wells A: In vitro invasiveness of DU-145 human prostate carcinoma cells is modelated by EGF receptor-mediated signals. Clin Exp Metastasis 13: 407-419, 1995
252. Liu DF, Rabbani SA: Induction of urinary plasminogen activator by retinoic acid results in increased invasiveness of human prostate cancer cells PC-3. Prostate 27: 269-276, 1995
253. Jarrard DF, Blitz BF, Smith RC, Patai BL, Rukstalis DB: Effect of epidermal growth factor on prostate cancer cell line PC3 growth and invasion. Prostate 24: 46-53, 1994
254. Pinski J, Reile H, Halmos G, Groot K, Schally AV: Inhibitory effects of somatostatin analogue RC-160 and bombesin/gastrin-releasing peptide antagonist RC-3095 on the growth of the androgen-independent Dunning R-3327-AT-1 rat prostate cancer. Cancer Res 54: 169-174, 1994
255. Pinski J, Reile H, Halmos G, Groot K, Schally AV: Inhibitory effects of analogs of uteinizing hormone-releasing hormone on the growth of the androgen-independent Dunning R-3327-AT-1 rat prostate cancer. Int J Cancer 59: 51-55, 1994
256. Kim JH, Sherwood ER, Sutkowski DM, Lee C, Kozlowski JM: Inhibition of prostatic tumor cell proliferation by suramin: alterations in TGF alpha-mediated autocrine growth regulation and cell cycle distribution. J Urol 146: 171-176, 1991
257. Cohen P, Peehl DM, Rosenfeld RG: The IGF axis in the prostate. [Review]. Horm Metab Res 26: 81-84, 1994
258. Kaicer EK, Blat C, Harel L: IGF-I and IGF-binding proteins: stimulatory and inhibitory factors secreted by human prostatic adenocarcinoma cells. Growth Factors 4: 231-237, 1991
259. Iwamura M, Sluss PM, Casamento JB, Cockett AT: Insulin-like growth factor I: action and receptor characterization in human prostate cancer cell lines. Prostate 22: 243-252, 1993
260. Pietrzkowski Z, Mudholland G, Gomella L, Jameson BA, Wernicke D, Baserga R: Inhibition of growth of prostatic cancer cell lines by peptide analogues of insulin-like growth factor 1. Cancer Res 53: 1102-1106, 1993
261. Polychronakos C, Janthly U, Lehoux JF, Koutsilieris M: Mitogenic effects of insulin and insulin-like growth factors on PA-III rat prostate adenocarcinoma cells:characterization of the receptors involved. Prostate 19: 313-321, 1991
262. Culig Z, Hobich A, Cronauer MV, Radmayr C, Trapman J, Hittmair A, Bartsch G, Klocker H: Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Res 54: 5474-5478, 1994
263. Koutsilieris M, Polychronakos C: Proteinolytic activity against IGF-binding proteins involved in the paracrine interactions between prostate adenocarcinoma cells and osteoblasts. Anticancer Res 12: 905-910, 1992
264. Janssen T, Kiss R, Dedecker R, Petein M, Pasteels JL, Schulman C: Influence of dihydrotestosterone, epidermal growth factor, and basic fibroblast growth factor on the cell kinetics of the PC3, DU145, and LNCaP prostatic cancer cell lines: relationship with DNA ploidy level. Prostate 27: 277-286, 1995
265. Cleave ME, Hsieh JT, von Eschenbach AC, Chung LW: Prostate and bone fibroblasts induce human prostate cancer growth in vivo: implications for bidirectional tumor-stromal cell interaction in prostate carcinoma growth and metastasis. J Urol 147: 1151-1159, 1992
266. Nelson JB, Hedican SP, George DJ, Reddi AH, Piantadosi S, Eisenberger MA, Simons JW: Identification of endothelin-1 in the pathophysiology of metastaticadenocarcinoma of the prostate. Nature Med 1: 944-949, 1995
267. Nelson JB, Chan-Tack K, Hedican SP, Magnuson SR, Opgenorth TH, Bova GS, Simons JW: Endothelin-1 production and decreased endothin B receptor expression in advanced prostate cancer. Cancer Res 56: 663-668, 1996
268. Kobayashi S, Tang R, Wang B, Opgenorth T, Stein E, Shapiro E, Lepor H: Localization of endothelin receptors in the human prostate. J Urol 151: 763-766, 1994
269. Warner TD, de Nucci G, Vane JR: Rat endothelin is a vasodilator in the isolated perfused mesentery of the rat. Eur J Pharmacol 159: 325-326, 1989
270. Hirata Y, Emori T, Eguchi S, Kanno K, Imai T, Ohta K, Marumo F: Endothelin receptor subtype B mediates the synthesis of nitric oxide by bovine endothelial cells. J Clin Invest 91: 1367-1373, 1993
271. Kitasjima I, Kawahara K, Nakajima T, Soekima Y, Matsuyama T, Maruyama I: Nitric oxide-mediated apoptosis in mastocytoma. Biochem Biophys Res Commun 203: 244-251, 1994
272. Xie K, Huang S, Dong Z, Juang SH, Gutman M, Xie OW, Nathan C, Fidler IJ: Transfection with the inducible nitric oxide synthase gene suppresses the tumorigenicity and abrogates metastasis by K-1735 murine melanoma cells. J Exp Med 181: 1333-1343, 1995
273. Goligorsky MS, Tsukahara H, Magazine H, Anderson TT, Malik AB, Bahou WF: Termination of endothelin signalling: role of nitric oxide. J Cell Physiol 158: 485-494, 1994
274. Boulanger C, Luscher TF: Release of endothelin from the porcine aorta: inhibition by endothelin-derived nitric oxide. J Clin Invest 85: 587-590, 1990
275. Graham CW, Lynch JH, Djakiew D: Distribution of nerve growth factor-like protein and nerve growth factor receptor in human benign prostatic hyperplasia and prostatic adenocarcinoma. J Urol 147: 1444-1447, 1992
276. Djakiew D, Pflug B, Onoda M: Stromal-epithelial paracrine interactions in the neoplastic rat and human prostate. Adv Exp Med Biol 330: 185-202, 1993
277. Djakiew D, Delsite R, Pflug B, Wrathall J, Lynch JH, Onoda M: Regulation of growth by a nerve growth factor-like protein which modulates paracrine interactions between a neoplastic epithelial cell line and stromal cells of the human prostate. Cancer Res 51: 3304-3310, 1991
278. Djakiew D, Pflug BR, Delsite R, Onoda M, Lynch JH, Arand G, Thompson EW: Chemotaxis and chemokinesis of human prostate tumor cell lines in response to human prostate stromal cell secretory proteins containing a nerve growth factor-like protein. Cancer Res 53: 1416-1420, 1993
279. Yang G, Wheeler TM, Kattan MW, Scardino PT, Thompson TC: Perineural invasion of prostate carcinoma cells is associated with reduced apoptotic index. Cancer 78: 1267-1271, 1996
280. Horigome K, Bullock ED, Johnson EM Jr: Effects of nerve growth factor on rat peritoneal mast cells. Survival promotion and immediate-early gene induction. J Biol Chem 269: 2695-2702, 1994
281. Smith RC, Litwin MS, Lu Y, Zelter BR: Identification of an endogenous inhibitor of prostatic carcinoma cell growth. Nature Med 1: 1040-1044, 1996
282. Cipolla BG, Ziade J, Hansard JY, Moulinoux JP, Staerman F, Quemener V, Lobel B, Guille F: Pretherapeutic erythrocyte polyamine spermine levels discriminate high risk relapsing patients with M1 prostate carcinoma. Cancer 78: 1055-1065, 1996
283. Costello LC, Franklin RB: Effect of prolactin on the prostate. [Review]. Prostate 24: 162-166, 1994
284. Janssen T, Darro F, Petein M, Raviv G, Pasteels JL, Kiss R, Schulman CC: In vitro characterization of prolactin-induced effects on proliferation in the neoplastic LNCaP, DU145 and PC3 models of the human prostate. Cancer 77: 144-149, 1996
285. Rana A, Habib FK, Halliday P, Ross M, Wild R, Elton RA, Chisholm GD: A case for synchronous reduction of testicular androgen, adrenal androgen and prolactin for the treatment of advanced carcinoma of the prostate [see comments]. Eur J Cancer 31A: 871-875, 1995
286. Heino J: Biology of tumor cell invasion: interplay of cell adhesion and matrix degradation. Int J Cancer 65: 717-722, 1996
287. Jewell K, Kapron-Bras C, Jeevaratnam P, Dedhar S: Stimulation of tyrosine phosphorylation of distinct proteins in response to antibody-mediated ligation and clustering of alpha 3 and alpha 6 integrins. J Cell Sci 108: 1165-1174, 1995
288. Knox JD, Cress AE, Clark V, Manriquez L, Affinito KS, Dalkin BL, Nagle RB: Differential expression of extracellular matrix molecules and the alpha 6-integrins in the normal and neoplastic prostate. Am J Pathol 145: 167-174, 1994
289. Nagle RB, Knox JD, Wolf C, Bowden GT, Cress AE: Adhesion molecules, extracellular matrix, and proteases in prostate carcinoma. J Cell Biochem Suppl 19: 232-237, 1994
290. Cress AE, Rabinovitz I, Zhu W, Nagle RB: The alpha 6 beta 1 and alpha 6 beta 4 integrins in human prostate cancer progression. Cancer Metastasis Rev 14: 219-228, 1995
291. Cress AE, Rabinovitz I, Zhu W, Nagle RB: The alpha 6 beta 1 and alpha 6 beta 4 integrins in human prostate cancer progression. [Review]. Cancer Metastasis Rev 14: 219-228, 1995
292. Nagle RB, Hao J, Knox JD, Dalkin BL, Clark V, Cress AE: Expression of hemidesmosomal and extracellular matrix proteins by normal and malignant human prostate tissue. Am J Pathol 146: 1498-1507, 1995
293. Rabinovitz I, Nagle RB, Cress AE: Integrin alpha 6 expression in human prostate carcinoma cells is associated with a migratory and invasive phenotype in vitro and in vivo. Clin Exp Metastasis 13: 481-491, 1995
294. Dedhar S, Saulnier R, Nagle R, Overall CM: Specific alterations in the expression of alpha 3 beta 1 and alpha 6 beta 4 integrins in highly invasive and metastatic variants of human prostate carcinoma cells selected by in vitro invasion through reconstituted basement membrane. Clin Exp Metastasis 11: 391-400, 1993
295. Coppolino M, Migliorini M, Argraves WS, Dedhar S: Identification of a novel form of the alpha 3 integrin subunit: covalent association with transferrin receptor. Biochem J 306: 129-134, 1995
296. Rossi MC, Zetter BR: Selective stimulation of prostatic carcinoma cell proliferation by transferrin. Proc Natl Acad Sci USA 89: 6197-7201, 1992
297. Sokoloff MH, Tso CL, Kaboo R, Taneja S, Pang S, deKernion JB, Belldegrun AS: In vitro modulation of tumor progression-associated properties of hormone refractory prostate carcinoma cell lines by cytokines. Cancer 77: 1862-1872, 1996
298. Witkowski CM, Rabinovitz I, Nagle RB, Affinito KS, Cress AE: Characterization of integrin subunits, cellular adhesion and tumorgenicity of four human prostate cell lines. J Cancer Res Clin Oncol 119: 637-644, 1993
299. Paul R, Jarrard DF, Bussemakers MJ, Nguyen SH, Bova GS, Schalken JA, Isaacs WB: Loss of P-cadherin expression in prostate cancer. Eur Urol 30(52), 1996 (Abstract)
300. Isaacs WB, Bova GS, Morton RA, Bussemakers MJ, Brooks JD, Ewing CM: Genetic alterations in prostate cancer. [Review]. Cold Spring Harb Symp Quant Biol 59: 653-659, 1994
301. Umbas R, Schalken JA, Aalders TW, Carter BS, Karthaus HF, Schaafsma HE, Debruyne FM, Isaacs WB: Expression of the cellular adhesion molecule E-cadherin is reduced or absent in high-grade prostate cancer. Cancer Res 52: 5104-5109, 1992
302. Cheng L, Nagabhushan M, Pretlow TP, Amini SB, Pretlow TG: Expression of E-cadherin in primary and metastatic prostate cancer. Am J Pathol 148: 1375-1380, 1996
303. Ross JS, Figge HL, Bui HX, del Rosario AD, Fisher HA, Nazeer T, Jennings TA, Ingle R, Kim DN: E-cadherin expression in prostatic carcinoma biopsies: correlation with tumor grade, DNA content, pathologic stage, and clinical outcome. Mod Pathol 7: 835-841, 1994
304. Giroldi LA, Schalken JA: Decreased expression of the intercellular adhesion molecule E-cadherin in prostate cancer: biological significance and clinical implications. Cancer Metastasis Rev 12: 29-37, 1993
305. Umbas R, Isaac WB, Bringuier PP, Schaafsma HE, Karthaus HF, Oosterhof GO, Debruyne FM, Schalken JA: Decreased E-cadherin expression is associated with poor prognosis in patients with prostate cancer. Cancer Res 54: 3929-3933, 1994
306. Bussemakers MJ, Van Moorselaar RJ, Giroldi LA, Ichikawa T, Isaacs JT, Takeichi M, Debruyne FM, Schalken JA: Decreased expression of E-cadherin in the progression of rat prostatic cancer. Cancer Res 52: 2916-2922, 1992
307. Giroldi LA, Schalken JA: Decreased expression of the intercellular adhesion molecule E-cadherin in prostate cancer: biological significance and clinical implications. [Review]. Cancer Metastasis Rev 12: 29-37, 1993
308. Graff JR, Herman JG, Lapidus RG, Chopra H, Xu R, Jarrard DF, Isaacs WB, Pitha PM, Davidson NE, Baylin SB: E-cadherin expression is silenced by DNA hypermethylation in human breast and prostate carcinomas. Cancer Res 55: 5195-5199, 1995
309. Schalken JA, Smit F, Bringuier PP, van Bokhoven A, Debruyne FM, Bussemakers MJ: The role of E-cadherin mutations in bladder and prostate cancer; is E-cadherin a classical suppressor gene? J Urol 155: 339A, 1996
310. Ewing CM, Ru N, Morton RA, Robinson JC, Wheelock MJ, Johnson KR, Barrett JC, Isaacs WB: Chromosome 5 suppresses tumorigenicity of PC3 prostate cancer cells: correlation with re-expression of alpha-catenin and restoration of E-cadherin function. Cancer Res 55: 4813-4817, 1995
311. Birchmeier W, Behrens J: Cadherin expression in carcinomas: role in the formation of cell junctions and the prevention of invasiveness. Biochim Biophys Acta 1109: 11-26, 1994
312. Hulsken J, Birchmeier W, Behrens J: E-cadherin and APC compete for the intraction with beta catenin and the cytoskeleton. J Cell Biol 127: 2061-2069, 1994
313. Carruba G, Miceli D, D'Amico D, Farruggio R, Comito L, Montesanti A, Polito L, Castagnetta LA: Sex steroids up-regulate E-cadherin expression in hormone-responsive LNCaP human prostate cancer cells. Biochem Biophys Res Commun 212: 624-631, 1995
314. Prall F, Nollau P, Neumaier M, Haubeck HD, Drzeniek Z, Helmchen U, Loning T, Wagener C: CD66a (BGP), an adhesion molecule of the carcinoembryonic antigen family, is expressed in epithelium, endothelium, and myeloid cells in a wide range of normal human tissues. J Histochem Cytochem 44: 35-41, 1996
315. Hsieh JT, Lin SH: Androgen regulation of cell adhesion molecule gene expression in rat prostate during organ degeneration. C-CAM belongs to a class of androgen-repressed genes associated with enriched stem/amplifying cell population after prolonged castration. J Biol Chem 269: 3711-3716, 1994
316. Kleinerman DI, Troncoso P, Lin SH, Pisters LL, Sherwood ER, Brooks T, von Eschenbach AC, Hsieh JT: Consistent expression of an epithelial cell adhesion molecule (C-CAM) during human prostate development and loss of expression in prostate cancer: implication as a tumor suppressor. Cancer Res 55: 1215-1220, 1995
317. Lin SH, Luo W, Earley K, Cheung P, Hixson DC: Structure and function of C-CAM1: effects of the cytoplasmic domain on cell aggregation. Biochem J 311: 239-245, 1995
318. Hsieh J-T, Luo W, Song W, Wang Y, Kleinerman DI, Van NT, Lin SH: Tumour suppressive role of an androgen-regulated epithelial cell adhesion molecule (C-CAM) in prostate carcinoma cell revealed by sense and antisense approaches. Cancer Res 55: 190-197, 1995
319. Kleinerman DI, Zhang WW, Lin SH, Nguyen TV, von Eschenbach AC, Hsieh JT: Application of a tumor suppressor (C-CAM1)-expressing recombinant adenovirus in androgen-independent human prostate cancer therapy: a preclinical study. Cancer Res 55: 2831-2836, 1995
320. Wolff JM, Stephenson RN, Chisholm GD, Habib FK: Levels of circulating intercellular adhesion molecule-1 in patients with metastatic cancer of the prostate and benign prostatic hyperplasia. Eur J Cancer 31A: 339-341, 1995
321. Folkman J: Angiogenesis in cancer, vascular, rheumatoid and other disease. Nature Med 1: 27-31, 1995
322. Lokeshwar VB, Lokeshwar BL, Pham HT, Block NL: Association of elevated levels of hyaluronidase, a matrix-degrading enzyme, with prostate cancer progression. Cancer Res 56: 651-657, 1996
323. Folkman J, Hanahan D: Switch to the angiogenic phenotype during tumorigenesis. [Review]. Princess Takamatsu Symp 22: 339-347, 1991
324. Holmgren L, O'Reilly MS, Folkman J: Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nature Med 1: 149-153, 1995
325. Brown LF, Yeo KT, Berse B, Morgentaler A, Dvorak HF, Rosen S: Vascular permeability factor (vascular endothelial growth factor) is strongly expressed in the normal male genital tract and is present in substantial quantities in semen. J Urol 154: 576-579, 1995
326. Moon SY, Yoon JH, Moon WC, Seo KK, Ki YJ: Role of angiogenesis and vascular endothelial growth factor in glandular hyperplasia of rat ventral prostate. J Urol 155 (Suppl): 463A, 1996
327. Bertrand N, Jonca F, Moro F, Soedrello S, Malavaud B, Cussenot O, Rischman P, Sarramon JP, Toulouse JP: In vitro regulation of VEGF expression in epithelial prostatic cells by testosterone. J Urol 155 (Suppl): 603A, 1996
328. Freeman MR, Schneck FX, Gagnon ML, Corless C, Soker S, Niknejad K, Peoples GE, Klagsbrun M: Peripheral blood T lymphocytes and lymphocytes infiltrating human cancers express vascular endothelial growth factor: a potential role for T cells in angiogenesis. Cancer Res 55: 4140-4145, 1995
329. Vukanovic J, Isaacs JT: Linomide inhibits angiogenesis, growth, metastasis, and macrophage infiltration within rat prostatic cancers. Cancer Res 55: 1499-1504, 1995
330. Chen C, Parangi S, Tolentino MJ, Folkman J: A strategy to discover circulating angiogenesis inhibitors generated by human tumors. Cancer Res 55: 4230-4233, 1995
331. Vukanovic J, Hartley-Asp B, Isaacs JT: Inhibition of tumor angiogenesis and the therapeutic ability of linomide against rat prostatic cancers. Prostate 26: 235-246, 1995
332. Vukanovic J, Passaniti A, Hirata T, Traystman RJ, Hartley-Asp B, Isaacs JT: Antiangiogenic effects of the quinoline-3-carboxamide linomide. Cancer Res 53: 1833-1837, 1993
333. Vukanovic J, Isaacs JT: Human prostatic cancer cells are sensitive to programmed (apoptotic) death induced by the antiangiogenic agent linomide. Cancer Res 55: 3517-3520, 1995
334. Siegal JA, Yu E, Brawer MK: Topography of neovascularity in human prostate carcinoma. Cancer 75: 2545-2551, 1995
335. Hall MC, Troncoso P, Pollack A, Zhau HY, Zagars GK, Chung LW, von Eschenbach AC: Significance of tumor angiogenesis in clinically localized prostate carcinoma treated with external beam radiotherapy. Urology 44: 869-875, 1994
336. Weidner N, Carroll PR, Flax J, Blumenfeld W, Folkman J: Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol 143: 401-409, 1993
337. Brawer MK, Deering RE, Brown M, Preston SD, Bigler SA: Predictors of pathologic stage in prostatic carcinoma. The role of neovascularity. Cancer 73: 678-687, 1994
338. Rosen PJ, Mendoza EF, Landaw EM, Mondino B, Graves MC, McBride JH, Turcillo P, DeKernion J, Belldegrun A: Suramin in hormone-refractory metastatic prostate cancer: a drug with limited efficacy. J Clin Oncol 14: 1626-1636, 1996
339. Dawson NA, Cooper MR, Figg WD, Headlee DJ, Thibault A, Bergan RC, Steinberg SM, Sausville EA, Myers CE, Sartor O: Antitumor activity of suramin in hormone-refractory prostate cancer controlling for hydrocortisone treatment and flutamide withdrawal as potentially confounding variables. Cancer 76: 453-462, 1995
340. Firsching A, Nickel P, Mora P, Allolio B: Antiproliferative and angiostatic activity of suramin analogues. Cancer Res 55: 4957-4961, 1995
341. Meyer GE, Yu E, Siegal JA, Petteway JC, Blumenstein BA, Brawer ML: Serum basic fibroblast growth factor in men with and without prostate carcinoma. Cancer 76: 2304-2311, 1995
342. Mohler JL: Cellular motility and prostatic carcinoma metastases. [Review]. Cancer Metastasis Rev 12: 53-67, 1993
343. Stearns ME, Stearns M: Autocrine factors, type IV collagenase secretion and prostatic cancer cell invasion. [Review]. Cancer Metastasis Rev 12: 39-52, 1993
344. Doyle GM, Sharief Y, Mohler JL: Prediction of metastatic potential by cancer cell motility in the Dunning R-3327 prostatic adenocarcinoma in vivo model. J Urol 147: 514-518, 1992
345. Pienta KJ, Murphy BC, Isaacs WB, Isaacs JT, Coffey DS: Effect of pentosan, a novel cancer chemotherapeutic agent, on prostate cancer cell growth and motility. Prostate 20: 233-241, 1992
346. Stearns ME, Wang M: Immunoassays of the metalloproteinase (MMP-2) and tissue inhibitor of metalloproteinase (TlMP 1 and 2) levels in noninvasive and metastatic PC-3 clones: effects of taxol. Oncol Res 6: 195-201, 1994
347. Stearns ME, Wang M, Stearns M: IL-10 blocks collagen IV invasion by 'invasion stimulating factor' activated PC-3 ML cells: upregulation of TIMP-1 expression. Oncol Res 7: 157-163, 1995
348. Lokeshwar BL, Selzer MG, Block NL, Gunja-Smith Z: Secretion of matrix metalloproteinases and their inhibitors (tissue inhibitor of metalloproteinases) by human prostate in expiant cultures: reduced tissue inhibitor of metalloproteinase secretion by malignant tissues. Cancer Res 53: 4493-4498, 1993
349. Powell WC, Knox JD, Navre M, Grogan TM, Kittelson J, Nagle RB, Bowden GT: Expression of the metalloproteinase matrilysin in DU-145 cells increases their invasive potential in severe combined immunodeficient mice. Cancer Res 53: 417-422, 1993
350. Pajouh MS, Nagle RB, Breathnach R, Finch JS, Brawer MK, Bowden GT: Expression of metalloproteinase genes in human prostate cancer. J Cancer Res Clin Oncol 117: 144-150, 1991
351. Knox JD, Wolf C, McDaniel K, Clark V, Loriot M, Bowden GT, Nagle RB: Matrilysin expression in human prostate carcinoma. Mol Cardinog 15:: 57-63, 1996
352. Baker T, Tickle S, Wasan H, Docherty A, Isenberg D, Waxman J: Serum metalloproteinases and their inhibitors: markers for malignant potential. Br J Cancer 70: 506-512, 1994
353. Hsu DW, Efird JT, Hedley-Whyte ET: Prognostic role of urokinase-type plasminogen activator in human gliomas. Am J Pathol 147: 114-123, 1995
354. Achibarou A, Kaiser S, Tremblay G, Ste-Marie LG, Brodt P, Goltzman D: Urokinase over-production results in increased skeletal metastasis by prostate cancer in vitro. Cancer Res 54: 2373-2377, 1994
355. Keer HN, Gaylis FD, Kozlowski JM, Kwaan HC, Bauer KD, Sinha AA, Wilson MJ: Heterogeneity in plasminogen activator (PA) levels in human prostate cancer cell lines: increased PA activity correlates with biologically aggressive behavior. Prostate 18: 201-214, 1991
356. Hille B: Ionic Channels of Excitable Membranes. Sunderland, Massachusetts: Sinauer Associates Inc. 1992
357. Cohen-Armon M, Sokolovsky M: Evidence for involvement of the voltage-dependent Na+ channel gating in depolarization-induced activation of G-proteins. J Biol Chem 268: 9824-9838, 1993
358. Woodfork KA, Wonderlin WF, Peterson VA, Strobl JS: Inhibition of ATP-sensitive potassium channels causes reversible cell-cycle arrest of human breast cancer cells in tissue culture. J Cell Physiol 162: 163-171, 1995
359. Wonderlin WF, Woodfork KA, Strobl JS: Changes in membrane potential during the progression of MCF-7 human mammary tumor cells through the cell cycle. J Cell Physiol 165: 177-185, 1995
360. Kondo S, Yin D, Morimura T, Kubo H, Nakatsu S, Takeuchi J: Combination therapy with cisplatin and nifedipine induces apoptosis in cisplatin-sensitive and cisplatin-resistant human glioblastoma cells. Br J Cancer 71: 282-289, 1995
361. Van Dolah FM, Ramsdell JS: Maitotoxin, a calcium channel activator, inhibits cell cycle progression through the G1/S and G2/M transitions and prevents CDC2 kinase activation in GH4Cl cells. J Cell Physiol 166: 49-56, 1996
362. Nagy P, Panyi G, Jenei A, Bene L, Gaspar R Jr, Matko J, Damjanovich S: Ion-channel activities regulate transmembrane signaling in thymocyte apoptosis and T-cell activation. Immunol Lett 44: 91-95, 1995
363. Arcangeli A, Becchetti A, Mannini A, Mugnai G, De Filippi P, Tarone G, Del Bene MR, Barletta E, Wanke E, Olivotto M: Integrin-mediated neurite outgrowth in neuroblastoma cells depends on the activation of potassium channels. J Cell Biol 122: 1131-1143, 1993
364. Isom LL, Ragsdale DS, De Jongh KS, Westenbroek RE, Reber BF, Scheuer T, Catterall WA: Structure and function of the beta 2 subunit of brain sodium channels, a transmembrane glycoprotein with a CAM motif. Cell 83: 433-442, 1995
365. Becchetti A, Arcangeli A, Del Bene MR, Olivotto M, Wanke E: Response to fibronectin-integrin interaction in leukaemia cells: delayed enhancing of a K+ current. Proc R Soc Lond B Biol Sci 248: 235-240, 1992
366. Watsky MA: Loss of keratocyte ion channels during wound healing in the rabbit cornea. Invest Ophthalmol Vis Sci 36: 1095-1099, 1995
367. Schwab A, Wojnowski L, Gabriel K, Oberleithner H: Oscillating activity of a Ca(2+)-sensitive K+ channel. A prerequisite for migration of transformed Madin-Darby canine kidney focus cells. J Clin Invest 93: 1631-1636, 1994
368. Bokvist K, Eliasson L, Ammala C, Renstrom E, Rorsman P: Co-localization of L-type Ca2+ channels and insulin-containing secretory granules and its significance for the initiation of exocytosis in mouse pancreatic B-cells. EMBO J 14: 50-57, 1995
369. Sheng ZH, Rettig J, Cook T, Catterall WA: Calcium-dependent interaction of N-type calcium channels with the synaptic core complex. Nature 379: 451-454, 1996
370. Pancrazio JJ, Tabbara IA, Kim YI: Voltage-activated K+ conductance and cell proliferation in small-cell lung cancer. Anticancer Res 13: 1231-1234, 1993
371. Higgins CF: Volume-activated chloride currents associated with the multidrug resistance P-glycoprotein. [Review]. J Physiol (Lond) 482: 31S-36S, 1995
372. Yamashita N, Hamada H, Tsuruo T, Ogata E: Enhancement of voltage-gated Na+ channel current associated with multidrug resistance in human leukemia cells. Cancer Res 46: 3736-3741, 1987
373. Neher E: Nobel lecture. Ion channels for communication between and within cells. [Review]. Neuron 8: 605-612, 1992
374. Grimes JA, Fraser SP, Stephens GJ, Downing JE, Laniado ME, Foster CS, Abel PD, Djamgoz MB: Differential expression of voltage-activated Na+ currents in two prostatic tumour cell lines: contribution to invasiveness in vitro. FEBS Lett 369: 290-294, 1995
375. Laniado ME, Lalani E-N, Fraser SP, Grimes JA, Bhangal G, Djamgoz MB, Abel PD: Expression and functional analysis of voltage-activated Na+ channels in human prostate cancer cell lines and their contribution to invasion in vitro. Am J Pathol 1997 (in press)
376. + currents distinguish LNCaP and PC-3 cell lines. Eur Urol 30(52):434, 1996 (Abstract)
377. Marino AA, Iliev IG, Schwalke MA, Gonzalez E, Marler KC, Flanagan CA: Association between cell membrane potential and breast cancer. Tumour Biol 15: 82-89, 1994
378. Wonderlin WF, Woodfork KA, Strobl JS: Changes in membrane potential during the progression of MCF-7 human mammary tumor cells through the cell cycle. J Cell Physiol 165: 177-185, 1995
379. Schwab A, Gabriel K, Finsterwalder F, Folprecht G, Greger R, Kramer A, Oberleithner H: Polarized ion transport during migration of transformed Madin-Darby canine kidney cells. Pflugers Arch 430: 802-807, 1995
380. ++-dependent endonuclease as an early event in castration-induced prostatic cell death. Prostate 13: 103-118, 1988
381. Martikainen P, Isaacs JT: Role of calcium in the programmed death of rat prostatic glandular cells. Prostate 17: 175-188, 1990
382. Furuya Y, Lundmo P, Short AD, Gill DL, Isaacs JT: The role of calcium, pH, and cell proliferation in the programmed (apoptotic) death of androgen-independent prostatic cancer cells induced by thapsigargin. Cancer Res 54: 6167-6175, 1994
383. Connor J, Sawczuk IS, Benson MC, Tomashefsky P, O'Toole KM, Olsson CA, Buttyan R: Calcium channel antagonists delay regression of androgen-dependent tissues and suppress gene activity associated with cell death. Prostate 13: 119-130, 1988
384. McDonnell T, von Eschenbach A, Marin M, Fernandez A, Westin P, Shi-Ming T, Brisbay S, Bick R, Buju L, McConkey D: Bel-2 confers resistance to cell death induction by androgen-ablation and chemotherapy in prostate cancer cells. J Urol 155 (Suppl): 527, 1996
385. Steinsapir J, Socci R, Reinach P: Effects of androgen on intracellular calcium of LNCaP cells. Biochem Biophys Commun 179: 90-96, 1991
386. Batra S, Popper LD, Hartley-Asp B: Effect of calcium and calcium antagonists on 45Ca influx and cellular growth of human prostatic tumor cells. Prostate 19: 299-311, 1991
387. Peppelenbosch MP, Tertoolen LG, De Laat SW, Zivkovic D: Ionic responses to epidermal growth factor in zebrafish cells. Exp Cell Res 218: 183-188, 1995
388. Misra RP, Bonni A, Miranti CK, Rivera VM, Sheng M, Greenberg ME: L-type voltage-sensitive calcium channel activation stimulates gene expression by a serum response factor-dependent pathway. J Biol Chem 26: 25483-25493, 1994
389. Matsunaga H, Nishimoto I, Kojima I, Yamashita N, Kurokawa K, Ogata E: Activation of a calcium-permeable cation channel by insulin-like growth factor II in BALB/c 3T3 cells. Am J Physiol 255: C442-446, 1988
390. Kanzaki M, Shibata H, Morgami H, Kojima I: Expression of calcium-permeable cation channel CD20 accelerates progression through the G1 phase in Balb/c 3T3 cells. J Biol Chem 270: 13099-13104, 1995
391. Huang Y, Rane SG: Potassium channel induction by the Ras/Raf signal transduction cascade. J Biol Chem 269: 31183-31189, 1994
392. Brown MJ, Loew LM: Electric field-directed fibroblast locomotion involves cell surface molecular reorganization and is calcium independent. J Cell Biol 127: 117-128, 1994
393. Carter HB, Partin AW, Coffey DS: Prediction of metastatic potential in an animal model of prostate cancer: flow cytometric quantification of cell surface charge. J Urol 142: 1338-1341, 1989
394. Carter HB, Coffey DS: Cell surface charge in predicting metastatic potential of aspirated cells from the Dunning rat prostatic adenocarcinoma model. J Urol 140: 173-175, 1988
395. Ware JL, Paulson DF, Mickey GH, Webb KS: Spontaneous metastasis of cells of the human prostate carcinoma cell line PC-3 in athymic nude mice. J Urol 128: 1064-1067, 1982
396. Sherwood ER, Berg LA, Mitchell NJ, McNeal JE, Kozlowski JM, Lee C: Differential cytokeratin expression in normal, hyperplastic and malignant epithelial cells from human prostate. J Urol 143: 167-171, 1990
397. Nagle RB, Ahmann FR, McDaniel KM, Paquin ML, Clark VA, Celniker A: Cytokeratin characterization of human prostatic carcinoma and its derived cell lines. Cancer Res 47: 281-286, 1987
398. Pang S, Taneja S, Dardashti K, Cohan P, Kaboo R, Sokoloff M, Tso CL, deKernion JB, Belldegrun AS: Prostate tissue specificity of the prostate-specific antigen promoter isolated from a patient with prostate cancer. Human Gene Therapy 6: 1417-1426, 1995
399. Israeli RS, Powell CT, Corr JG, Fair WR, Heston WD: Expression of the prostate-specific membrane antigen. Cancer Res 54: 1807-1811, 1994
400. Kostenuik PJ, Sanchez-Sweatman O, Orr FW, Singh G: Bone cell matrix promotes the adhesion of human prostatic carcinoma cells via the α2β1 integrin. Clin Exp Metastasis 14: 19-26, 1996
401. Dedhar S, Jewell K, Rojiani M, Gray V: The receptor for the basement membrane glycoprotein entactin is the integrin alpha 3/beta 1. J Biol Chem 267: 18908-18914, 1992
402. Rokhlin OW, Cohen MB: Expression of cellular adhesion molecules on human prostate tumor cell lines. Prostate 26: 205-212, 1995
403. Fan K: Heterogeneous subpopulations of human prostatic adenocarcinoma cells: potential usefulness of P21 protein as a predictor for bone metastasis. J Urol 139: 318-322, 1988